40 results about "Intra peritoneal" patented technology

A medical treatment system, such as a peritoneal dialysis system, may include control and other features to enhance patient comfort and ease of use. For example, the peritoneal dialysis system may include a control system that can adjust a volume of fluid infused into a peritoneal cavity to prevent intraperitoneal fluid volume from exceeding a pre-determined amount. The control system can adjust by adding one or more therapy cycles, allowing for fill volumes during each cycle of the one or more therapy cycles to be reduced. The control system may continue to allow the fluid to drain from the peritoneal cavity as completely as possible before starting a next therapy cycle of the one or more therapy cycles. The control system may also adjust a dwell time of the fluid within the peritoneal cavity during the one or more therapy cycles in order to complete a therapy within a scheduled time period. A cycler may also be configured to have a heater control system that monitors both a temperature of a heating tray and a temperature of a bag of dialysis fluid in order to bring a temperature of the dialysis fluid rapidly to a specified temperature, with minimal temperature overshoot.

Trocar components and methods of use are described, wherein the trocar components are configured to provide access to intraperitoneal space via the rectouterine pouch to surgical tools, which optionally include one or more surgical robot members. The surgical tools are optionally 5 mm or more in diameter. In some embodiments, a cannula part has a lumen sized to provide to a plurality of the surgical tools simultaneous transvaginal access to the intraperitoneal space via the rectouterine pouch. In some embodiments, an incision sized to receive a distal aperture of the cannula is created, optionally using one or two dilators. The dilators are sized to create (optionally starting from a puncture by a needle 2 mm in diameter or less) an oblong aperture. In some embodiments, the oblong aperture is at least twice as wide across a long diameter as across a short diameter.An access port for sealing an opening of a natural orifice and supplying access to a body cavity through the natural orifice including: a sealing unit; an unobstructed single lumen cannula extending to the body cavity; a connector connecting the cannula to the sealing unit; an access opening through the sealing unit to the single lumen; a cap including a plurality of cap openings configured to seal between medical instruments inserted into the openings and the access opening.

The present invention describes a trocar assembly and a method of use, wherein the trocar assembly is configured to provide access to the intraperitoneal space to a surgical tool through the rectouterine pouch, the surgical tool optionally including one or more surgical robot components. The diameter of the surgical tool is optionally 5 mm or greater. In some embodiments, the cannula portion has an inner cavity that is sized to provide access to the intraperitoneal space via the rectouterine pouch simultaneously through the vagina to multiple surgical tools. In some embodiments, one or two dilators are optionally used to form an incision sized to receive the distal hole of the cannula. The size of the dilator can form (optionally, starting from puncture by a needle having a diameter of 2 mm or less) a rectangular hole. In some embodiments, the width of the rectangular hole on the major axis is at least twice the width on the minor axis.

A drug composition having the structure of formula I for the treatment of pain is provided. The drug can be given to an animal via oral, transdermal, rectal, intravenous, subcutaneous, sublingual or intraperitoneal administration, etc., thereby exerting an analgesic effect. The active components of the drug are convenient to prepare and easy to identify, and are structurally different from those of all other existing analgesic drugs, thus forming a novel class of effective analgesic compounds.

The invention relates to a liquid aqueous formulation of pyronaridine for use in medical treatment, said liquid aqueous formulation comprising at least 70 wt.% water and at least 40 µmol / ml of dissolved pyronaridine, having a pH in the range of 2.5 to 5.8 and being characterised in that the ratio of the osmolality of the formulation (in Osm / kg) to the pyronaridine concentration of the formulation (in mmol / mL) is less than 2.0. The invention also relates to a sterile liquid aqueous formulation comprising at least 70 wt.% water and at least 40 µmol / ml of dissolved pyronaridine, having an osmolality in the range of 0.15 to 0.60 Osm / kg, a pH in the range of 2.5 to 5.8 and being characterised in that the ratio of the osmolality of the formulation (in Osm / kg) to the pyronaridine concentration of the formulation (in mmol / mL) is less than 2.0. The concentrated aqueous pyronaridine formulation of the present invention is perfectly suited for intramuscular administration, but can also suitably be administered subcutaneously, intranasally, orally, intraperitonially or intravenously.

The invention relates to a composition and related methods for enhancing the immune response and / or decreasing the size or growth rate of a tumor volume in a subject. The composition comprises a recombinant MVA encoding IL-12 and, optionally, a Tumor Associated Antigen (“TAA”). In some embodiments, the MVA also encodes 4-1BBL and / or a second MVA encoding 4-1BBL is coadministered to the subject. In some embodiments of the invention, methods comprise injecting these MVAs intratumorally. In some embodiments, the recombinant MVAs are injected intraperitoneally to stimulate an immune response to peritoneal tumors.

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.

The present invention relates to a protective agent selected from the group consisting of L-glutamine, L-alanyl-L-glutamine, L-glutamyl-L-alanine, L-glutamyl-L-glycine, L-glycyl-L-glutamine, or a mixture thereof, and to a method for preparing the protective agent, the present invention relates to a protective agent for use in the prevention and / or treatment of diseases associated with end-stage nephropathy (ESKD) mediated by liver dysfunction induced by peritoneal dialysis treatment, specifically for the prevention and / or treatment during peritoneal dialysis treatment: (A) liver diseases induced by said peritoneal dialysis treatment and / or (B) diseases associated with ESKD mediated by liver dysfunction induced by said peritoneal dialysis treatment, wherein said protective agent is administered by intraperitoneal administration.

The invention discloses an application of an NFE2L2 inhibitor in preparation of a medicine for inhibiting growth of an endometriosis focus. The NFE2L2 inhibitor is ML385. It is proved for the first time that expression of the NFE2L2 in different types of endometriosis focuses (endometriosis focuses, ovarian endometriosis focuses and deep endometriosis focuses) is increased, and inhibition of the NFE2L2 can reduce the resistance of cells to an oxidative stress environment, increase ferroptosis sensitivity and reduce the viability of the cells; by applying the ML385, the growth of an endometriosis focus can be obviously inhibited, and a new treatment strategy is provided for treating the endometriosis.

The utility model relates to a puncture hole suturing device for laparoscopic surgery. The device includes a stapling body and a sleeve. The suturing body is used for suturing a puncture hole of a patient. The hollow-cylinder-shaped sleeve is provided with a hollow-cylinder-shaped guide sleeve piece which is fixedly connected with the sleeve in the mode that the axes are not collinear or staggered, so that the guide sleeve piece and the sleeve do not move relative to each other. The front suture section and the guide kit enter the body of a patient through a puncture hole of the patient in a mutually embedded mode. The front suture section can be embedded with the guide kit so as to avoid operation injury before, during and after implantation, suture direction deviation caused by rotation of the suture body can be avoided, operation stability is effectively improved, and the front suture section can be conveniently implanted into an abdominal cavity through a laparoscope puncture hole and sutured from an intraperitoneal line to the subcutaneous direction.

The utility model relates to oxygen supply equipment. The oxygen supply equipment at least comprises a circulation assembly and a treatment assembly. The circulating assembly is constructed to be used for conveying oxygen-supplied circulating liquid into a peritoneal cavity of a to-be-oxygen-supplied organism along a circulating flow channel and recycling to-be-treated circulating liquid in the peritoneal cavity of the to-be-oxygen-supplied organism from the circulating flow channel; the treatment assembly is constructed to at least provide oxygen for circulating liquid to be treated flowing through circulating liquid in the oxygen supply equipment, so that oxygen-supplied circulating liquid is obtained. As the peritoneum can be used as a semi-permeable membrane, the surface area is large, and the blood capillaries are rich, after the oxygen-supplied circulating liquid enters the peritoneal cavity of the organism to be supplied with oxygen, the oxygen-supplied circulating liquid can penetrate through the peritoneum to exchange oxygen with blood in the blood capillaries in the peritoneum, and therefore the aim that the oxygen-supplied circulating liquid can be used for oxygen supply under the condition that the respiratory function of a patient is damaged is achieved. And providing oxygen to the patient.

Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal (GI) tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Disclosed herein is a vaccine comprising a nanoemulsion and an immunogen non-covalently conjugated to the surface of the nanoemulsion by an amphiphilic linker, wherein the vaccine is suitable for inducing a mucosal antibody response in the gastrointestinal tract. Also disclosed are methods of using the vaccine to immunize a subject by intraperitoneal administration of an effective amount of the vaccine, alone or with an adjuvant.

Chimeric antigen receptors (CARs) are provided. When the CARs herein are expressed on the surface of immune cells, such immune cells may be directed to osteosarcoma cells. In a murine intraperitoneal model, the tumor growth was significantly delayed for T cells expressing a CAR comprising a scFv from TP1 or TP3 antibodies. Immune cells expressing the CARs herein display therapeutic effect in the form of decreased tumor volume in a murine model simulating metastatic osteosarcoma. Combined with the finding that stem cells from healthy bone marrow were not significantly affected by T cells expressing any of the CARs, the CARs may be used for the treatment of osteosarcoma.

Techniques for monitoring intraperitoneal volume (IPV) during a dwell period of a peritoneal dialysis patient include monitoring intraperitoneal pressure (IPP) during the dwell period using a pressure sensor, monitoring the density of the dialysate during the dwell period, and determining a change in IPV based at least on a change in IPP and a change in the density of the dialysate during the dwell period.

A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing, a first polymer that includes analyte indicator molecules and covers at least a portion of the housing, and a second polymer that forms an interpenetrating network with the first polymer. The second polymer may prevent biological or protein interference of the sensor.

Apparatuses comprising at least one processor and a memory coupled to the at least one processor, wherein the memory comprises instructions that when executed by the processor cause the processor to access prescription information for a peritoneal dialysis (RD) process for a patient and provide the prescription information as input to at least one computational model to determine a predicted intraperitoneal volume (IPV) or a predicted ultrafiltration volume (UFV) respectively, wherein the computational model is trained to determine the predicted IPV or UFV respectively based on the prescription information and patient information for at least one RD process cycle for the patient or a population of patients associated with the patient.

Trocar assemblies and methods of use are described in which trocar assemblies are configured to provide access to an intraperitoneal space through a rectal uterine recess to a surgical tool, optionally including one or more surgical robotic components. The diameter of the surgical tool is optionally 5 mm or greater. In some embodiments, the cannula portion has a lumen sized to provide access to a plurality of surgical tools via a rectal uterine recess while transvaginal access to an intraperitoneal space. In some embodiments, one or two dilators are optionally used to form an incision sized to receive the distal bore of the cannula. The dilator may be sized to form a rectangular hole (optionally beginning with puncturing by a needle having a diameter of 2 mm or less). In some embodiments, the rectangular aperture has a width on the major axis that is at least twice the width on the minor axis.

The present disclosure provides the use of a liposome suspension comprising transmembrane pH gradient liposomes in the treatment of acute hyperamminemia crisis (HAC) associated with innate metabolic error (IEM) in a subject, wherein the treatment comprises intraperitoneal administration of the liposome suspension to the subject and removal of a dialysate containing ammonia-loaded liposomes from the subject.

The present invention discloses a Acinetobacter baumannii immunogenic protein and its composition and application. This invention provides a protein, comprising 39 amino acids of the N-terminal α-helix part of the Ata protein transport functional domain of Acinetobacter baumannii and an adjuvant protein; amino acid sequence of said 39 amino acids of the N-terminal α-helix part of the Ata protein transport functional domain of Acinetobacter baumannii is shown as the 127th-165th amino acid residues of SEQ ID NO:2. In present invention the 39 amino acids of the N-terminal α-helix part of surface protein Ata (Acinetobacter trimeric autotransporter) of Acinetobacter baumannii, was took to fuse with CTB, and express in BL21. The protein was purified by a nickel column, and used to intraperitoneally immunize mouses by 2.5 μg / mouse. Its immunogenicity and immunoprotection was verified through the animal experiments, which proves it has a good effect of anti-infection of Acinetobacter baumannii.

The present disclosure provides a use of a liposomal suspension comprising transmembrane pH-gradient liposomes, for the treatment of an acute hyperammonemia episode (HAC) associated with inborn errors of metabolism (IEM) in a subject, wherein the treatment comprises intraperitoneally administering the liposomal suspension to the subject and removing a dialysate containing ammonia-loaded liposomes from the subject.

This invention relates to pharmaceutical compositions and methods for treating or preventing autoimmune diseases in patients or subjects in need, said pharmaceutical compositions comprising: a 5-benzylaminosalicylic acid compound represented by chemical formula (I) or a pharmaceutically acceptable salt thereof; and, for example, a pharmaceutically acceptable carrier suitable for oral, intraperitoneal, or intravenous administration. Compositions comprising a 5-benzylaminosalicylic acid compound of chemical formula (I) or a pharmaceutically acceptable salt thereof can be used to treat autoimmune diseases.

The application provides a new crown vaccine carrier and application thereof. Composed of SARS-CoV-2 RBD as an antigen and STING agonist diABZI coupled with yeast beta-glucan particles. Compared with the diABZI-RBD vaccine alone, the GP-diABZI-RBD vaccine shows sustained vaccine release and elicits a more persistent immune response in mice. Intraperitoneal injection of GP-diABZI-RBD in mice can cause significant cellular and humoral immune responses. Using a replicable virus-like particle system based on pseudovirus particles, we determined that this vaccine can effectively induce effective and persistent neutralizing antibodies against the prototype and VOC, respectively. In particular, the prototype RBD antigen provided by the GP-diABZI-RBD vaccine shows a stronger and longer humoral immune response and antiviral protection.

Described herein is a hydrophobic anti-cancer drug encapsulated into poly(alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.

Disclosed are: a system comprising a gas circulation device capable of circulating hyperthermic gas in the peritoneal cavity and a temperature control device; and a system comprising a drug spray device for effectively spraying a drug in the peritoneal cavity together with gas. The systems of the present invention are used as systems for hyperthermic intraperitoneal chemotherapy and can maximize the anticancer therapy effect by more effectively delivering a small amount of an anticancer drug to cancer cells while maintaining the temperature of gas in the peritoneal cavity at a predetermined temperature.

A method of treating metabolic dysfunction-associated steatotic liver disease in a patient, reducing hepatic fat accumulation in a patient, and / or eliminating hepatic fat in a patient can include administering a therapeutically effective amount of Pam3CysSerLys4 (Pam3CSK4) to the patient in need thereof. The therapeutically effective amount of Pam3CysSerLys4 may be administered via an Intraperitoneal (IP) injection.

A surgical device or a portion of a surgical device places a purse string suture in tissue within a body (e.g., an intraperitoneal space). The surgical device includes or a distal end effector for a surgical device includes a jaw assembly, a staple cartridge, and a suture.

Therapeutics and methods of treating a stroke in a patient comprising delivering stem cells into a peritoneum of the patent. According to a further embodiment the stem cells are mesenchymal stem cells. According to a further embodiment the stem cells are human placenta mesenchymal stem cells (hPMSC). According to a further embodiment the stroke is one of stroke is one of occlusive, post-occlusive, hemorrhagic, and transient ischemic injury. According to a further embodiment the method further comprises the step of delivering a clot busting compound into a blood stream of the patient.

Methods are provided for potent mRNA vaccines for treatment of cancers with a mutation in the ras gene family. Methods for stimulating system immune responses and treatment are provided, including intratumoral, intravenous, intramuscular, intradermal, intraperitoneal (i.p.), or subcutaneous injection of the composition as disclosed herein.

The invention relates to an implantable artificial kidney and a use method thereof, and the implantable artificial kidney comprises an implantable micro pump, a suction tube piece, a percolate conveying tube, a flow sensor, a pressure sensor, a creatinine urea online detection module, a control chip, a battery, a charging induction coil, an in-vitro charger and a mobile phone APP or a computer terminal, and continuous or intermittent micro-suction is performed on the outer side of the peritoneum for 24 hours to form negative pressure of the outer side of the peritoneum to the inner side of the peritoneum, so that liquid, water and solute (including toxins) on the inner side of the peritoneum convect to the outer side of the peritoneum to form percolate, and the percolate is guided into the bladder through the percolate conveying pipe and is discharged out of the body through normal urination of the human body. According to the implantable artificial kidney and the use method thereof, the design is reasonable, a more effective treatment effect is brought to a renal failure patient, the life quality of the patient can be obviously improved, the life cycle of the patient can be prolonged, and the treatment cost of the patient can be reduced.